BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24415648)

  • 1. Insights into wild-type and mutant p53 functions provided by genetically engineered mice.
    Donehower LA
    Hum Mutat; 2014 Jun; 35(6):715-27. PubMed ID: 24415648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
    Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M
    Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation.
    Nakayama M; Sakai E; Echizen K; Yamada Y; Oshima H; Han TS; Ohki R; Fujii S; Ochiai A; Robine S; Voon DC; Tanaka T; Taketo MM; Oshima M
    Oncogene; 2017 Oct; 36(42):5885-5896. PubMed ID: 28628120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accumulation of somatic mutations in TP53 in gastric epithelium with Helicobacter pylori infection.
    Shimizu T; Marusawa H; Matsumoto Y; Inuzuka T; Ikeda A; Fujii Y; Minamiguchi S; Miyamoto S; Kou T; Sakai Y; Crabtree JE; Chiba T
    Gastroenterology; 2014 Aug; 147(2):407-17.e3. PubMed ID: 24786892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in p53 research: an interdisciplinary perspective.
    Olivier M; Petitjean A; Marcel V; Pétré A; Mounawar M; Plymoth A; de Fromentel CC; Hainaut P
    Cancer Gene Ther; 2009 Jan; 16(1):1-12. PubMed ID: 18802452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 mutations in human cancer: database reassessment and prospects for the next decade.
    Leroy B; Anderson M; Soussi T
    Hum Mutat; 2014 Jun; 35(6):672-88. PubMed ID: 24665023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [TP53 mutations and molecular epidemiology].
    Otsuka K; Ishioka C
    Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 in breast cancer subtypes and new insights into response to chemotherapy.
    Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
    Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probing p53 biological functions through the use of genetically engineered mouse models.
    Attardi LD; Donehower LA
    Mutat Res; 2005 Aug; 576(1-2):4-21. PubMed ID: 16038709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trp53 null and R270H mutant alleles have comparable effects in regulating invasion, metastasis, and gene expression in mouse colon tumorigenesis.
    Tang J; Feng Y; Kuick R; Green M; Green M; Sakamoto N; Kurosu Y; Lin J; Cho KR; Fearon ER
    Lab Invest; 2019 Oct; 99(10):1454-1469. PubMed ID: 31148594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant TP53 disrupts age-related accumulation patterns of somatic mutations in multiple cancer types.
    Zhang W; Flemington EK; Zhang K
    Cancer Genet; 2016 Sep; 209(9):376-380. PubMed ID: 27751354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of p53, p63, and p73 to the developmental diseases and cancer.
    Tomkova K; Tomka M; Zajac V
    Neoplasma; 2008; 55(3):177-81. PubMed ID: 18348649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 20 years studying p53 functions in genetically engineered mice.
    Donehower LA; Lozano G
    Nat Rev Cancer; 2009 Nov; 9(11):831-41. PubMed ID: 19776746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.
    Petitjean A; Achatz MI; Borresen-Dale AL; Hainaut P; Olivier M
    Oncogene; 2007 Apr; 26(15):2157-65. PubMed ID: 17401424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome.
    Palmero EI; Achatz MI; Ashton-Prolla P; Olivier M; Hainaut P
    Curr Opin Oncol; 2010 Jan; 22(1):64-9. PubMed ID: 19952748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of telomere length shortening with TP53 somatic mutations, polymorphisms and allelic loss in breast tumors and esophageal cancer.
    Hao XD; Yang Y; Song X; Zhao XK; Wang LD; He JD; Kong QP; Tang NL; Zhang YP
    Oncol Rep; 2013 Jan; 29(1):226-36. PubMed ID: 23124483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection for loss of p53 function in T-cell lymphomagenesis is alleviated by Moloney murine leukemia virus infection in myc transgenic mice.
    Baxter EW; Blyth K; Cameron ER; Neil JC
    J Virol; 2001 Oct; 75(20):9790-8. PubMed ID: 11559812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wild-type p53 in cancer cells: when a guardian turns into a blackguard.
    Kim E; Giese A; Deppert W
    Biochem Pharmacol; 2009 Jan; 77(1):11-20. PubMed ID: 18812169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 from basic research to clinical applications.
    Tominaga O; Hamelin R; Remvikos Y; Salmon RJ; Thomas G
    Crit Rev Oncog; 1992; 3(3):257-82. PubMed ID: 1616957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.